{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?nctId=NCT02243579",
    "query": {
      "nctId": "NCT02243579"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T01:04:33.227Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02243579",
      "title": "Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Mycosis Fungoides and Sezary Syndrome",
        "Refractory Mycosis Fungoides and Sezary Syndrome",
        "Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7",
        "Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7",
        "Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7",
        "Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7",
        "Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7",
        "Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7",
        "Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2014-10-15",
      "completion_date": "2019-04-01",
      "has_results": true,
      "last_update_posted_date": "2019-09-20",
      "last_synced_at": "2026-09-29T01:04:33.227Z",
      "location_count": 8,
      "location_summary": "Palo Alto, California • New Haven, Connecticut • Tampa, Florida + 5 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02243579"
    }
  ]
}